Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

Clinical trial NCT06005597 · COMPLETED

Trial details

NCT number: NCT06005597
Sponsor: NewAmsterdam Pharma
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Dyslipidemias Hypercholesterolemia Familial Hypercholesterolemia ASCVD High Cholesterol

Start date: 2024-03-01
Primary completion: 2024-09-25
Enrollment: 407

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.